Top Gynecologic Cancer Research to Look Forward to At ASCO 2026

Patients with gynecologic cancers may soon hear about new advances in immunotherapy, antibody-drug conjugates (ADCs), vaccines and even cell therapies during the 2026 ASCO Annual Meeting.

This year’s meeting will feature several studies in ovarian, endometrial and cervical cancers that could help shape future treatment approaches — especially for patients whose disease has returned or stopped responding to standard therapies.

Here are some of the key gynecologic cancer presentations to watch at ASCO 2026.

Long-term immunotherapy results in endometrial cancer

One of the most anticipated gynecologic cancer presentations will focus on long-term survival results from the phase 3 RUBY trial, which studied the immunotherapy drug Jemperli (dostarlimab-gxly) plus chemotherapy in patients with advanced or recurrent endometrial cancer. The presentation will be given by Dr. Matthew A. Powell of Washington University School of Medicine.

The study specifically looked at patients whose tumors were mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), biomarkers that can make tumors more responsive to immunotherapy.

Researchers will present updated long-term survival and “cure modeling” data, which may help doctors better understand how many patients could experience durable benefit from treatment.

Immunotherapy has already changed the treatment landscape in endometrial cancer, and these new findings could provide a clearer picture of how long responses may last.

New options may be emerging in platinum-resistant ovarian cancer

Several studies at ASCO will focus on platinum-resistant ovarian cancer, an area where new treatments are urgently needed because the disease can become difficult to treat after standard chemotherapy stops working.

One study will present overall survival data for gotistobart combined with Keytruda pembrolizumab. The presentation will be led by Dr. Joyce N. Barlin of St. Peters Health. Researchers are evaluating whether adding immunotherapy to treatment may help patients live longer.

Another highly watched study involves Elahere (mirvetuximab soravtansine-gynx), an antibody-drug conjugate (ADC) already used in some ovarian cancer settings. Dr. Philipp Harter will present findings from the phase 3 trial evaluating the therapy in patients with platinum-sensitive ovarian cancer whose tumors express folate receptor alpha.

ADCs are designed to deliver cancer-fighting medicine directly to tumor cells while limiting damage to healthy tissue. These treatments have become one of the fastest-growing areas in cancer research.

Researchers will also present findings on several additional ADCs being studied in ovarian cancer, including:

• Dr. Toon Van Gorp presenting research on the NaPi2b-targeting ADC TUB040
• Dr. Gini F. Fleming presenting data on the c-Met-targeting ADC telisotuzumab adizutecan

ADC research expands into cervical cancer

Another study to watch involves datopotamab deruxtecan-dlnk, a TROP2-directed ADC being studied in recurrent cervical cancer. The presentation will be given by Dr. Jianli Zhao.

TROP2 has become an important target across several cancer types, and researchers hope this type of targeted therapy could offer another treatment option for patients whose cervical cancer has progressed after prior therapy.

Because recurrent cervical cancer can be difficult to treat, many experts are closely watching how ADCs may fit into future care. Researchers will also hear data from Dr. Tudor-Eliade Ciuleanu on another investigational TROP2-targeted ADC called CBR-701 in metastatic cervical cancer.

Cell therapy and vaccines continue moving into gynecologic cancers

Some of the most experimental research at ASCO will focus on cell therapy and cancer vaccines. One early-phase study is evaluating a PRAME-directed T-cell receptor (TCR) therapy in ovarian cancer. Dr. Antonia Busse of Berlin School of Integrative Oncology will present the findings.

This type of treatment works by engineering immune cells to better recognize and attack cancer cells. Although the research is still in early stages, it reflects growing interest in bringing personalized immune-based therapies into gynecologic cancers.

Researchers will also present findings from the TEDOVA trial, which is studying the cancer vaccine OSE2101 with or without Keytruda (pembrolizumab) in platinum-sensitive recurrent ovarian cancer. The study will be presented by Dr. Alexandra Leary of Gustave Rousse in London.

Cancer vaccines are designed to train the immune system to recognize and fight cancer cells, and investigators hope they could someday help keep disease under control for longer periods of time.

Hormonal and targeted therapy combinations remain an area to watch

Another presentation will examine Verzenio (abemaciclib) plus hormonal therapy in recurrent ovarian and endometrial cancers. The study will be presented by Dr. Jordyn Silverstein of UCLA Health.

Abemaciclib is a CDK4/6 inhibitor, a type of targeted therapy already used in breast cancer. Researchers are studying whether combining the drug with hormonal therapy could help slow cancer growth in some gynecologic cancers.

As researchers continue searching for treatments that may be easier to tolerate than traditional chemotherapy, these types of combination approaches remain important to watch.

Looking ahead

This year’s ASCO Annual Meeting highlights how quickly gynecologic cancer research continues to evolve. While some studies could potentially influence treatment decisions in the near future, others offer an early look at therapies that may shape the next generation of care.

For patients, the meeting represents continued progress toward more personalized treatment options and new strategies for difficult-to-treat gynecologic cancers.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.